Prognostic significance of pre-treatment immune-inflammation biomarkers in anal cancer: A study combining real-world data and a meta-analysis

Genitourinary Cancer

Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study

Prostate Cancer Prostatic Dis

Stopka-Farooqui U, Stavrinides V, Simpson BS, Qureshi H, Carmona Echevierra LM, Pye H, Ahmed Z, Alawami MF, Kay JD, Olivier J, Heavey S, Patel D, Freeman A, Haider A, Moore CM, Ahmed HU, Whitaker HC

doi: 10.1038/s41391-024-00920-1

Further Publications

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

J Natl Cancer Inst

Zerdes I, Filis P, Fountoukidis G, El-Naggar AI, Kalofonou F, D'Alessio A, Pouptsis A, Foukakis T, Pentheroudakis G, Ahlgren J, Smith D, Valachis A

doi: 10.1093/jnci/djaf015

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

Lung Cancer

Nadal E, Rifi N, Kane S, Mbacke S, Starkman L, Suero B, Le H, Samjoo IA

doi: 10.1016/j.lungcan.2024.107816

Gastrointestinal Cancer

Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study

Int J Cancer

Marschner N, Haug N, Hegewisch-Becker S, Reiser M, Dörfel S, Lerchenmüller C, Linde H, Wolf T, Hof A, Kaiser-Osterhues A, Potthoff K, Jänicke M, TPK‐Group (Tumour Registry Pancreatic Cancer)

doi: 10.1002/ijc.35071

Genitourinary Cancer

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis

Eur J Cancer

Stucki M, Dosch S, Gnädinger M, Graber SM, Huber CA, Lenzin G, Strebel RT, Zwahlen DR, Omlin A, Wieser S

doi: 10.1016/j.ejca.2024.114072

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Breast Cancer

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Eur J Cancer

Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L

doi: 10.1016/j.ejca.2024.115113

Gastrointestinal Cancer

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Int J Cancer

van Nassau SCMW, Zwart K, van der Baan FH, Vink GR, Elferink MAG, Snaebjornsson P, May AM, Koopman M, Roodhart JML

doi: 10.1002/ijc.35410

Related content

Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis

Advancing Breast Cancer Treatment with Elacestrant

Results of TRODELVY® real-world data

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Results of TRODELVY^® real-world data